drugset / Trial / NCT04922008
Stage I HER2 Positive Invasive Breast Cancer De-escalation Study(IRIS-C/D)
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This is an open label, phase II study evaluating the efficacy and safety of trastuzumab combined with oral chemotherapy (capecitabine or vinorelbine) in patients with HER-2 positive stage I breast cancer.
Timeline
- Start
- 2021-07-01
- Primary completion
- 2024-06-30
- Completion
- 2026-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Capecitabine | Small molecule | — | Oral |
| Subject | Vinorelbine | Small molecule | — | Oral |
| Background | Trastuzumab | Monoclonal antibody | — | — |